

Regular Meeting of the

Santa Clara County Health Authority Pharmacy and Therapeutics (P&T) Committee

Thursday, June 17, 2021, 6:00 - 8:00 PM

Santa Clara Family Health Plan

6201 San Ignacio Ave, San Jose, CA 95119

Via Teleconference

(408) 638-0968

Meeting ID: 854 0622 0567

Passcode: **SCFHP2021**

<https://us06web.zoom.us/j/85406220567>

AGENDA

1. Roll Call / Establish Quorum	Dr. Lin	6:00	5 min
2. Public Comment Members of the public may speak to any item not on the agenda; two minutes per speaker. The Committee reserves the right to limit the duration of the public comment period to 30 minutes.	Dr. Lin	6:05	5 min
3. Open Meeting Minutes Review Santa Clara Family Health Plan (SCFHP) 1Q 2021 P&T Open Session Minutes. Possible Action: Approve SCFHP P&T Open Session Minutes	Dr. Lin	6:10	2 min
4. Standing Agenda Items			
a. Chief Medical Officer Health Plan Updates	Dr. Nakahira	6:12	5 min
b. Medi-Cal Rx Update	Dr. Huynh	6:17	1 min
c. Grievance & Appeals Report – 1Q 2021	Mr. Breakbill	6:18	5 min
d. Plan/Global Medi-Cal Drug Use Review	Dr. Otomo	6:23	4 min
i. Drug Utilization Evaluation Update			
ii. DHCS DUR Annual Survey			
e. Emergency Supply Report – 2Q 2020	Dr. Nguyen	6:27	2 min
Adjourn to Closed Session			
<i>Pursuant to Welfare and Institutions Code Section 14087.36 (w)</i>			
5. Closed Meeting Minutes Review SCFHP 1Q 2021 P&T Closed Session Minutes. Possible Action: Approve SCFHP P&T Closed Session Minutes	Dr. Lin	6:29	2 min
6. Metrics & Financial Updates			
a. Membership Report	Dr. Nakahira	6:31	3 min
b. Pharmacy Dashboard	Dr. Otomo	6:34	2 min
c. Drug Utilization & Spend – 1Q 2021	Dr. McCarty	6:36	5 min

<p>7. Discussion and Recommendations for Changes to SCFHP's Medical Benefit Drug Prior Authorization Grid</p> <p>a. Medical Benefit Drug PA Grid Modifications Possible Action: Approve Medical Benefit Drug Prior Authorization Grid Addition and Modification Recommendations</p>	Dr. Otomo	6:41	3 min
<p>8. Discussion and Recommendations for Changes to SCFHP's Cal MediConnect Formulary & Coverage Determination Criteria</p> <p>a. Pharmacy Benefit Manager 1Q 2021 P&T Minutes b. Pharmacy Benefit Manager 2Q 2021 P&T Part D Actions Possible Action: Approve MedImpact Minutes & Actions</p>	Dr. McCarty	6:44	3 min
<p>9. Discussion and Recommendations for Changes to SCFHP's Medi-Cal Formulary & Prior Authorization Criteria</p> <p>a. Old Business/Follow-Up b. Formulary Modifications Possible Action: Approve Formulary Addition and Modification Recommendations</p>	Dr. Lin	6:47	1 min
<p>c. Fee-for-Service Contract Drug List Comparability Possible Action: Approve CDL Comparability Formulary Recommendations</p>	Dr. Otomo	6:48	3 min
<p>d. Prior Authorization Criteria</p>	Dr. McCarty	6:51	3 min
<p>i. <u>New/Revised Criteria</u></p> <ol style="list-style-type: none"> 1. Adcirca (tadalafil) 2. Tecfidera (dimethyl fumarate) 3. Amitiza (lubiprostone) 4. Brand Name 5. Copaxone (glatiramer acetate) 6. Gilenya (fingolimod) 7. Humira (adalimumab) 	Dr. Nguyen	6:54	5 min
<p>ii. <u>Annual Review</u></p> <ol style="list-style-type: none"> 1. Androgel (testosterone gel) 2. Ciprodex (ciprofloxacin/dexamethasone) 3. Diabetic Supplies 4. Dovonex (calcipotriene) 5. Elmiron (pentosan polysulfate) 6. Exelon (rivastigmine) 7. Hycet (hydrocodone/acetaminophen sol) 8. Intron A (interferon alfa-2b) 9. Lovaza (omega-3 acid ethyl esters) 10. Lysteda (tranexamic acid) 11. Makena (hydroxyprogesterone caproate) 12. Malarone (atovaquone/proguanil) 13. Marinol (dronabinol) 14. Mavyret (glecaprevir/pibrentasvir) 15. Mycobutin (rifabutin) 16. Nebupent (pentamidine) 17. Oral liquids – Non-formulary 18. Pain Medications – Terminally Ill 19. Provigil (modafinil) 20. Reauthorization 			

21. Restasis, Cequa (cyclosporine)
22. Revatio (sildenafil)
23. Santyl (collagenase)
24. Sporanox (itraconazole)
25. Symlin (pramlintide)
26. Tymlos (abaloparatide)
27. Viroptic (trifluridine)
28. Xenazine (tetrabenazine)
29. Hepatitis C
30. Rhopressa (netarsudil)
31. Oncology
32. Epclusa (sofosbuvir/velpatasvir)

Possible Action: Approve PA Criteria Recommendations

10. New Drugs and Class Review

- a. S1P Receptor Modulators – Multiple Sclerosis
- b. Pulmonary Arterial Hypertension
- c. Oral Azole Antifungals
- d. Actinic Keratosis
- e. Farxiga – Chronic Kidney Disease
- f. New Entities – Tepmetko, Qelbree
- g. New Formulations – Vesicare LS, Bronchitol, Elepsia XR, Roszet
- h. New Indications – Gocovri, Actemra, Praluent
- i. New & Expanded Indications – *Informational Only*

Dr. Le	6:59	10 min
Dr. McCarty	7:09	50 min

Possible Action: Approve New Drug and Class Recommendations

Reconvene in Open Session

11. Discussion Items

- a. New and Generic Pipeline

Dr. McCarty	7:59	1 min
-------------	------	-------

12. Adjournment

Next meeting Thursday September 16, 2021

Dr. Lin	8:00
---------	------

Notice to the Public—Meeting Procedures

- Persons wishing to address the Committee on any item on the agenda are requested to advise the Recorder so that the Chairperson can call on them when the item comes up for discussion.
- The Committee may take other actions relating to the issues as may be determined following consideration of the matter and discussion of the possible action.
- In compliance with the Americans with Disabilities Act, those requiring accommodations in this meeting should notify Nancy Aguirre 48 hours prior to the meeting at 408-874-1835.
- To obtain a copy of any supporting document that is available, contact Nancy Aguirre at 408-874-1835. Agenda materials distributed less than 72 hours before a meeting can be inspected at the Santa Clara Family Health Plan offices at 6201 San Ignacio Ave, San Jose, CA 95119.

This agenda and meeting documents are available at www.scfhp.com